Compare Incyte Corporation (INCY) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Marriott International Inc — how do they compare? Incyte Corporation trades at $117.96 (market cap $23.11B), while Marriott International Inc trades at $367.56 (market cap $96.76B). The key difference: Marriott International Inc is far larger — about 4.2× Incyte Corporation's market cap, and Marriott International Inc pays a 0.8% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MAR | |
|---|---|---|
Market Cap | $23.11B | $96.76B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $402.54 |
52-Week Low | $67.38 | $255.35 |
Enterprise Value | $19.13B | $113.71B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Marriott International (MAR) trades at $366.83, up 0.16% on the day, with technical indicators showing a bearish trend near key support at $364. The company reported Q1 2026 EPS of $2.72, beating expectations, and maintains a net income margin of 9.72% amid steady revenue growth. Recent developments include a strategic partnership with Coca-Cola and the launch of an AI-powered travel search tool, Ask Bonvoy, enhancing its digital offerings.
The outlook is mixed: analyst consensus targets $387.92 with 44% buy ratings, but rising debt-to-asset ratios and hotel owner disputes over the Bonvoy program pose risks. Earnings on August 3, 2026, will be critical for confirming growth trajectory amid competitive travel sector pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
